45 citations
,
April 2021 in “Current Treatment Options in Oncology” ADT for prostate cancer may harm the heart, but GnRH antagonists might be safer.
26 citations
,
June 1983 in “Journal of Hypertension” Minoxidil lowers blood pressure more effectively but has more side effects, so try hydralazine first.
1 citations
,
March 2009 in “The Journal of Urology” Combination therapy with fesoterodine and doxazosin improves bladder function and delays BPH progression.
6 citations
,
August 2017 in “Physiological Research” Setipiprant may reduce inflammation by blocking an enzyme called aldose reductase.
8 citations
,
October 2016 in “Journal of Investigative Dermatology” MR antagonists may improve skin health and wound healing, especially in aging.
3 citations
,
August 2020 in “Cutaneous and Ocular Toxicology” ATP helps prevent skin damage from vandetanib by reducing stress.
May 2024 in “Reactions weekly”
14 citations
,
November 2006 in “Current Medicinal Chemistry” New treatments for enlarged prostate are being developed to be more effective and have fewer side effects.
23 citations
,
May 2019 in “Expert Opinion on Therapeutic Patents” New androgen receptor modulators show promise for treating diseases like prostate cancer and muscle wasting.
September 2024 in “Journal of the American Academy of Dermatology” AH-001 could be a safer and more effective treatment for hair loss.
129 citations
,
January 2004 in “Journal of medicinal chemistry” Researchers developed new compounds that target the androgen receptor effectively with fewer side effects.
19 citations
,
January 1993 in “Dermatologic Clinics” 123 citations
,
January 2012 in “The Keio Journal of Medicine” Anti-angiogenic therapy can help treat cancer but may cause resistance and side effects, so alternative methods are being explored.
July 2024 in “Reactions Weekly”
1 citations
,
January 2021 in “Research Square (Research Square)” Enzalutamide, a prostate cancer drug, may help prevent COVID-19 by blocking the virus from entering lung cells.
April 2017 in “The Journal of urology/The journal of urology” SHH protein helps nerve regeneration in hypertensive rats.
April 2024 in “Expert opinion on emerging drugs” New treatments for male hair loss are being explored to improve effectiveness and reduce side effects.
February 2024 in “Cancers” New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.
68 citations
,
April 2002 in “Journal of Alternative and Complementary Medicine” Natural 5AR inhibitors effectively improve mild to moderate hair loss in men.
Combining dutasteride or finasteride with an α1 blocker is more effective for managing BPH than using either alone.
January 2019 in “Oncogen” Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.
52 citations
,
February 2006 in “Current pharmaceutical design” 5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.
17 citations
,
January 2015 in “MedChemComm” New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.
47 citations
,
January 2003 in “Current opinion in urology” A new drug, dutasteride, is at least as effective as the older drug, finasteride, for treating enlarged prostate and may have additional uses.
36 citations
,
July 2022 in “Journal of Medicinal Chemistry” Therapies targeting the androgen receptor are being developed to treat prostate cancer and improve bone and muscle health.
January 2019 in “Nihon Yakuri Gakkai nenkai yoshishu” Current treatments for lower urinary tract symptoms include α1-blockers, 5ARIs, PDE5 inhibitors, anticholinergic agents, and β3-adrenergic receptor agonists.
Self-monitoring blood pressure in pregnant women didn't improve outcomes, diabetes drugs may increase gallbladder disease risk, a new drug helps severe hair loss, a plant-based COVID-19 vaccine is 69.5% effective, and new anticoagulants are safer for diabetics with heart rhythm issues than warfarin.
5 citations
,
January 2014 in “Molecular Simulation” A new compound may treat benign prostatic hyperplasia better than finasteride.
June 2025 in “Revista Foco” JAK inhibitors effectively treat severe alopecia areata with manageable side effects.
October 2019 in “European heart journal” Androgen-deprivation therapies increase the risk of certain heart conditions, but testosterone treatment may help.